Apanix

Apnimed (formerly Apanix) is a clinical-stage pharmaceutical company focused on developing the first oral medical treatments for obstructive sleep apnea (OSA) and related disorders. The company's approach targets the underlying neurological causes of OSA, specifically the loss of upper airway muscle tone during sleep, rather than relying on physical devices like CPAP machines. Its lead candidate, AD109, is a first-in-class oral combination therapy currently in Phase 3 clinical trials designed to improve daytime sleepiness and overall quality of life for OSA patients. Apnimed's pipeline also includes AD504, a second-generation program aimed at optimizing the pharmacological profile for broader patient populations. Headquartered in Cambridge, Massachusetts, the company is backed by prominent life science investors and led by experts in sleep medicine and drug development.